Therefore, a potential, still unexplored treatment option could be represented by [177Lu]Lu-PSMA-PRRT in MTC cases showing substantial [68Ga]Ga-PSMA uptake [57•]. This evidence concerns the gene FOLH1 and medullary thyroid gland carcinoma.